The treatment of tuberculosis under current conditions

Cover Page

Cite item

Full Text

Abstract

Aim. Study of the current state of problems of treatment of patients with tuberculosis based on literature data and their own experience.

Materials and methods. In the Russian Federation, the number and proportion of patients with co-infection with HIV/tuberculosis continues to increase against the background of improvement in the main epidemiological indicants for tuberculosis. In 2017, 20.9% of newly diagnosed tuberculosis patients had HIV infection. The combination of the two infections significantly complicates the further improvement of the situation with tuberculosis, and the appearance of drug-resistant strains of Mycobacterium tuberculosis sometimes completely neutralizes the results of chemotherapy. The article describes the schemes of modern tuberculosis chemotherapy taking into account HIV/tuberculosis co-infection, as well as MDR in combination with surgical treatment methods, as well as analyzes the data of epidemiological monitoring of treatment of 1115 tuberculosis patients newly diagnosed in 2017 in Moscow, 360 tuberculosis patients with MDR MBT (cohort 2013–2014), the results of treatment with the use of new chemotherapy regimens for tuberculosis (bedaquiline, linezolid, moxifloxacin) in 36 patients, the effectiveness and safety of surgical methods in 192 patients.

Results. The application of new individualized anti-TB chemotherapy schedules in patients with HIV co-infection/tuberculosis with MDR-MBT has allowed to improve the treatment efficacy. The surgical intervention combined with modern chemotherapy regimens in patients with HIV/tuberculosis co-infection with MDR MBT has been proved to be effective and safe, contributes to the improving the results of treatment for this category of patients.

Conclusion. The confluence of two global problems of co-infection HIV/TB and MDR TB, significantly prevents from the end of the tuberculosis epidemic in the world. At the same time, advances in the development and implementation of new anti-TB drugs and surgical treatment methods give hope for significant progress for resolving this situation.

About the authors

M. V. Sinitsyn

Moscow Research and Clinical Center for Tuberculosis Control

Email: taxol@bk.ru
ORCID iD: 0000-0001-8951-5219

д.м.н., зам. дир. по научной и организационно-методической работе

Russian Federation, Moscow

M. V. Kalinina

Moscow Research and Clinical Center for Tuberculosis Control

Email: taxol@bk.ru
ORCID iD: 0000-0001-5327-496X

к.м.н., ст. науч. сотр., доц., врач-фтизиатр туберкулезного хирургического отд-ния

Russian Federation, Moscow

E. M. Belilovskiy

Moscow Research and Clinical Center for Tuberculosis Control

Email: taxol@bk.ru
ORCID iD: 0000-0002-3456-3069

к.м.н., зав. отд. эпидемиологического мониторинга туберкулеза

Russian Federation, Moscow

A. S. Galstyan

Moscow Research and Clinical Center for Tuberculosis Control

Email: taxol@bk.ru
ORCID iD: 0000-0002-9893-0841

врач-фтизиатр, зав. туберкулезным легочным отд-нием №1

Russian Federation, Moscow

M. N. Reshetnikov

Moscow Research and Clinical Center for Tuberculosis Control

Author for correspondence.
Email: taxol@bk.ru
ORCID iD: 0000-0002-4418-4601

к.м.н., врач-хирург туберкулезного хирургического отд-ния

Russian Federation, Moscow

D. V. Plotkin

Moscow Research and Clinical Center for Tuberculosis Control

Email: taxol@bk.ru
ORCID iD: 0000-0002-6659-7888

к.м.н., доц., врач-хирург туберкулезного хирургического отд-ния

Russian Federation, Moscow

References

  1. World Health Organization. Global Tuberculosis Report 2019. Geneva, 2019. https://www.who.int/tb/publications/global_report/en/
  2. Социально значимые заболевания населения России в 2018 году. Статистические материалы. Минздрав РФ, 2019 [Sotsial’no znachimye zabolevaniya naseleniya Rossii v 2018 godu (Statisticheskie materialy). Minzdrav RF, 2019 (In Russ.)]. https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2018-god
  3. Эпидемиологическая ситуация по туберкулезу в России, 2018. ЦНИИОИЗ Минздрава РФ, 2019 [Epidemiologicheskaia situatsiia po tuberkulezu v Rossii, 2018. TsNIIOIZ Minzdrava RF, 2019 (In Russ.)]. https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_ epidsituaciya.pdf
  4. Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018. Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. М.: МНПЦБТ, 2019 [Protivotuberkuleznaya rabota v gorode Moskve. Analiticheskii obzor statisticheskikh pokazatelei po tuberkulezu, 2018. Pod red. EM Bogorodskoi, VI Litvinova, EM Belilovskogo. Moscow: MNPTsBT, 2019 (In Russ.)].
  5. ТБ/ВИЧ в Российской Федерации. Эпидемиология, особенности клинических проявлений и результаты лечения. Под ред. С.А. Стерликова. М.: РИО ЦНИИОИЗ, 2017 [TB/VICh v Rossiiskoi Federatsii. Epidemiologiya, osobennosti klinicheskikh proyavlenii i rezul’taty lecheniya. Pod red. SA Sterlikova. Moscow: RIO TsNIIOIZ, 2017 (In Russ.)].
  6. Синицын М.В., Белиловский Е.М., Соколина И.А. и др. Внелегочные локализации туберкулеза у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(11):19-25. [Sinitsyn MV, Belilovsky EM, Sokolinа IA, et al. Extrapulmonary tuberculosis in HIV Patients. Tuberculosis and Lung Diseases. 2017;95(11):19-25 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-11-19-25
  7. Sacula A. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax. 1983;38:326-32. doi: 10.1136/thx.38.5.326
  8. Jacobaeus HV. Ur die Moglichkeitdie Zystoskopie bei Untersuchung seroser Hohlungen anzuwenden. Munchener Medizinische Wochenschrift. 1910;57;2090-2.
  9. Ghai SN. Extra pleural pneumonolysis with or without plombage in thoracoplasty failures: review of 21 cases. Indian J Tuberc. 1958;5(3):122-9.
  10. Tiberi S, Torrico MM, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Brasileiro Pneumologia. 2019;45(2):e20180324. doi: 10.1590/1806-3713/e20180324
  11. McDermott W, Muschenheim C, Hadley SD. Streptomycin in the treatment of tuberculosis in humans. J Clin Invest. 1947;26(6):1190.
  12. Рабухин А.Е. Туберкулез органов дыхания у взрослых. М.: Медицина, 1976 [Rabukhin AE. Respiratory tuberculosis in adults. Moscow: Meditsina, 1976 (In Russ.)].
  13. Хоменко А.Г. Химиотерапия туберкулеза легких. М.: Медицина, 1980 [Khomenko AG. Chemotherapy for pulmonary tuberculosis. Moscow: Meditsina, 1980 (In Russ.)].
  14. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis. 1991;(4 Pt 1):697-8. doi: 10.1164/ajrccm/143.4_Pt_1.697
  15. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5(Suppl. 3):S402-406. doi: 10.1093/clinids/5.supplement_3.s402
  16. Styblo K. Recent advances in epidemiological research in tuberculosis. Advances in Tuberculosis Research. 1980;20:1-63.
  17. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia-Los Angeles. 1981. MMWR Morb Mortal Wkly Rep. 1996;45(34):729-33.
  18. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-31. doi: 10.1056/NEJM198112103052401
  19. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171. doi: 10.1002/14651858. CD000171.pub3
  20. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171. doi: 10.1002/14651858.CD000171.pub2
  21. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009-21. doi: 10.1001/archinte.163.9.1009
  22. Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep. 2013;15:77-84. doi: 10.1007/s11908-012-0311-3
  23. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, 2016. https://www.nice.org.uk/guidance/ng33
  24. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One. 2012;7(3):e32482. doi: 10.1371/journal.pone.0032482
  25. Burmen B, Modi S, Cavanaugh JS, et al. Tuberculosis screening outcomes for newly diagnosed persons living with HIV, Nyanza Province, Kenya, 2009. Int J Tuberc Lung Dis. 2016;20(1):79-84. doi: 10.5588/ijtld.15.0053
  26. Зимина В.Н., Микова О.Е., Варецкая Т.А. и др. Выявление микобактерий туберкулеза в мокроте у больных ВИЧ-инфекцией при использовании современного алгоритма этиологической диагностики заболевания. Инфекционные болезни. 2018;16(1):28-34 [Zimina VN, Mikova OE, Varetskaya TA, et al. Detection of mycobacterium tuberculosis in sputum of patients with HIV infection using a modern algorithm of etiological diagnosis of disease. Infectious Diseases. 2018;16(1):28-34 (In Russ.)]. doi: 10.20953/1729-9225-2018-1-28-34
  27. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25(3):564-9. doi: 10.1183/09031936.05.00111304
  28. Слогоцкая Л.В., Синицын М.В., Кудлай Д.А. Возможности иммунологических тестов в диагностике латентной туберкулезной инфекции и туберкулеза. Туберкулез и болезни легких. 2019;97(11):46-58 [Slogotskaya LV, Sinitsyn MV, Kudlay DA. Potentialities of immunological tests in the diagnosis of latent tuberculosis infection and tuberculosis. Tuberculosis and Lung Diseases. 2019;97(11):46-58 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-11-46-58
  29. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-62. doi: 10.1086/597351
  30. WHO guidelines on tuberculosis infection prevention and control, 2019 update. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf?ua=1
  31. Савоненкова Л.Н., Рузов В.И., Колчин Д.В. и др. Трудности и ошибки диагностики абдоминального туберкулеза в практике терапевта. Терапевтический архив. 2019;91(11):16-9 [Savonenkova LN, Ruzov VI, Kolchin DV, et al. Difficulties and mistakes in the diagnosis of abdominal tuberculosis in the practice of the general practitioner. Therapeutic Archive. 2019;91(11):16-9 (In Russ.)]. doi: 10.26442/00403660.2019.11.000374
  32. Пантелеев А.М., Никулина О.В., Христусев А.С. и др. Дифференциальная диагностика туберкулеза и микобактериоза у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(10):47-52 [Panteleev AM, Nikulina OV, Khristusev AS, et al. Differential diagnostics of tuberculosis and mycobacteriosis in HIV patients. Tuberculosis and Lung Diseases. 2017;95(10):47-52 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-10-47-52
  33. Синицын М.В., Скопин М.С., Решетников М.Н. и др. Дифференциальная диагностика лимфаденопатии брюшной полости у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2019;97(2):5-11 [Sinitsyn MV, Skopin MS, Reshetnikov MN, et al. Differential diagnostics of abdomen lymphadenopathy in HIV patients. Tuberculosis and Lung Diseases. 2019;97(2):5-11 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-2-5-11
  34. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии. М.: МНПЦБТ, 2008 [Litvinov VI, Makarova MV, Krasnova MA. Non-tuberculous mycobacteria. Moscow: MNPTsBT, 2008 (In Russ.)].
  35. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-62. doi: 10.1164/rccm.167.4.603
  36. Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep. 1996;45(16):330-3.
  37. Туберкулез с множественной лекарственной устойчивостью. Под ред. И. Бастиан, Ф. Порталс. М.: Медицина и жизнь, 2003 [Multidrug-resistant tuberculosis. Pod red. I Bastian, F Portals. Moscow: Meditsina i zhizn’, 2003 (In Russ.)].
  38. A guide to monitoring and evaluation for collaborative TB/HIV activities, 2015 revision. World Health Organization, Geneva 2015. http://www.who.int/tb/publications/monitoring-evaluation-collaborative-tb-hiv/en/
  39. Hermans SM, Zinyakatira N, Caldwell J, et al. High rates of recurrent TB disease: a population-level cohort study. Clinical Infectious Diseases. 2020:ciaa470. doi: 10.1093/cid/ciaa470
  40. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39(4):807-19. doi: 10.1183/09031936.00203811
  41. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis. Clin Infect Dis. 2017; 64(12):1670-7. doi: 10.1093/cid/cix208
  42. Клинические рекомендации. Туберкулез у взрослых. Общероссийская общественная организация «Российское общество фтизиатров». Минздрав РФ, 2020 [Klinicheskie rekomendatsii. Tuberkulez u vzroslykh. Obshcherossiiskaya obshchestvennaya organizatsiya “Rossiiskoe obshchestvo ftiziatrov”. Minzdrav RF, 2020 (In Russ.)]. http://cr.rosminzdrav.ru/#!/recomend/943
  43. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
  44. Rapid communication: key changes to treatment of drug-resistant tuberculosis. World Health Organization, Geneva 2019. https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2019.pdf?ua=1
  45. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92(3):15-25. doi: 10.1016/j.ijid.2020.01.042
  46. Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):32-9. doi: 10.7326/M14-2979
  47. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. doi: 10.1183/13993003.00387-2017
  48. Calligaro G, Moodley L, Symons G, Dheda K. The medical and surgical treatment of drug-resistant tuberculosis. J Thora Dis. 2014;3(6):186-95. doi: 10.3978/j.issn.2072-1439.2013.11.11
  49. Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394-402. doi: 10.1183/13993003.01891-2015
  50. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-87. doi: 10.1016/j.jinf.2009.06.011
  51. Решетников М.Н., Скопин М.С., Синицын М.В. и др. Выбор хирургической тактики при перфоративных туберкулезных язвах кишечника у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(9):19-24 [Reshetnikov MN, Skopin MS, Sinitsyn MV, et al. The choice of surgical tactics in perforated tuberculous intestinal ulcers in HIV patients. Tuberculosis Lung Dis. 2017;95(9):19-24 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-9-19-24
  52. Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis. 2019;83:72-6. doi: 10.1016/j.ijid.2019.03.036
  53. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6-16. doi: 10.5588/ijtld.12.0198
  54. Kilani T, Boudaya MS, Zribi H, et al. Surgery for thoracic tuberculosis. Revue de Pneumologie Clinique. 2015;71(2-3):140-58. doi: 10.1016/j.pneumo.2014.03.005
  55. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13(5):780-2. doi: 10.3201/eid1305.070200
  56. Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017;145(3):271-93. doi: 10.4103/ijmr.IJMR_177_16
  57. Rao M, Ippolito G, Mfinanga S, et al. Improving treatment outcomes for MDR-TB – Novel host-directed therapies and personalized medicine of the future. Int J Infect Dis. 2019;3:62-7. doi: 10.1016/j.ijid.2019.01.039
  58. Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6): 645-62. doi: 10.5588/ijtld.18.0622
  59. Migliori GB, D’Ambrosio L, Centis R, et al. Guiding principles to reduce tuberculosis transmission in the WHO European region. World Health Organization Regional Office for Europe, Copenhagen 2018. http://www.euro.who.int/__data/assets/pdf_file/0008/377954/ic-principles-eng.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies